9 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitusRecruitingPhase 32026-10-08NCT07222332
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsNutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitusRecruitingPhase 32026-10-08NCT07222137
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic ArthritisSkin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, rheumatic disorderRecruitingPhase 32026-10-07NCT03773965
A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsCrohn disease, Digestive System Diseases, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, autoimmune disease, bone disorder, colitis, colonic disorder, connective tissue disorder, digestive system disorder, gastroenteritis, immune system disorder, inflammatory bowel disease, intestinal disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, psoriasis, psoriatic arthritis, rheumatic disorder, skin disorder, spondylitis, ulcerative colitis, vertebral column disorderRecruitingPhase 32026-09-25NCT06663332
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisDigestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitisActive, not recruitingPhase 32026-09-25NCT06260163
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseCrohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorderRecruitingPhase 32026-09-25NCT05923073
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorderActive, not recruitingPhase 32026-07-30NCT05559359
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyNeoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor, spinal cord disorder, spinal cord neoplasmActive, not recruitingPhase 22026-07-17NCT06413706
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumorslow grade gliomaRecruitingPhase 22025-04-10NCT04775485